Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 60 Carcinoma, Non-Small-Cell Lung 48 Lung Neoplasms 39 Head and Neck Neoplasms 26 Gliosarcoma 26 Squamous Cell Carcinoma of Head and Neck 25 Pancreatic Neoplasms 25 Central Nervous System Neoplasms 23 Brain Neoplasms 22 Rectal Neoplasms 21 Breast Neoplasms 17 Astrocytoma 17 Sarcoma 16 Neoplasms 16 Glioma 15 Uterine Cervical Neoplasms 14 Prostatic Neoplasms 14 Esophageal Neoplasms 14 Carcinoma, Squamous Cell 11 Lymphoma, Follicular 10 Leukemia 10 Melanoma 9 Lymphoma, Large B-Cell, Diffuse 9 Lymphoma 9 Leukemia, Lymphocytic, Chronic, B-Cell 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Lymphoma, Non-Hodgkin 8 Neoplasm Metastasis 7 Myelodysplastic Syndromes 7 Lymphoma, Mantle-Cell 7

Interventions

Imatinib Mesylate 2 spartalizumab 1 pembrolizumab 1 nilotinib 1 Thiotepa 1 Radiotherapy 1 Radiosurgery 1 Photochemotherapy 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1 Panobinostat 1 Nivolumab 1 Melphalan 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Dihematoporphyrin Ether 1 Cyclophosphamide 1 Cetuximab 1 Busulfan 1 Bone Marrow Transplantation 1 Blood Specimen Collection 1 Bacterial Load 1 Amifostine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Chordoma × Radiotherapy × Clear all

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Massachusetts General Hospital

Phase 1 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡